Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study.
Weiwei PengMaurits A den BoerSem TamaraNadia J MokiemSjors P A van der LansAlbert BondtDouwe SchultePieter-Jan HaasMonique C MinnemaSuzan H M RooijakkersArjan D van ZuilenAlbert J R HeckJoost SnijderPublished in: Journal of proteome research (2023)
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a predominant monoclonal antibody (i.e., M-protein) in serum, without clinical symptoms. Here we present a case study in which we detect MGUS by liquid-chromatography coupled with mass spectrometry (LC-MS) profiling of IgG1 in human serum. We detected a Fab-glycosylated M-protein and determined the full heavy and light chain sequences by bottom-up proteomics techniques using multiple proteases, further validated by top-down LC-MS. Moreover, the composition and location of the Fab-glycan could be determined in CDR1 of the heavy chain. The outlined approach adds to an expanding mass spectrometry-based toolkit to characterize monoclonal gammopathies such as MGUS and multiple myeloma, with fine molecular detail. The ability to detect monoclonal gammopathies and determine M-protein sequences straight from blood samples by mass spectrometry provides new opportunities to understand the molecular mechanisms of such diseases.
Keyphrases
- mass spectrometry
- liquid chromatography
- multiple myeloma
- high resolution mass spectrometry
- capillary electrophoresis
- monoclonal antibody
- gas chromatography
- high performance liquid chromatography
- tandem mass spectrometry
- single cell
- high resolution
- protein protein
- amino acid
- simultaneous determination
- solid phase extraction
- air pollution
- stem cells
- binding protein
- label free
- cell therapy
- small molecule
- depressive symptoms
- mesenchymal stem cells
- genetic diversity
- cell surface